SGLT2 Inhibitors Reduce Anemia Risk in Concomitant T2D, CKD SGLT2 Inhibitors Reduce Anemia Risk in Concomitant T2D, CKD

Initiating treatment with SGLT2 inhibitors vs GLP-1 RAs was linked to a 19% reduced risk for composite anemia outcomes in patients with T2D and CKD stages I-III.Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology Clinical Summary Source Type: news